Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study-Reference-Cited by-同舟云学术

Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study

Published:2021-06 Issue: Volume:327 Page:31-38
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Lepor Norman E.,Sun Jie^ORCID,Canton Gador^ORCID,Contreras Laurn^ORCID,Hippe Daniel S.,Isquith Daniel A.,Balu Niranjan^ORCID,Kedan Ilan^ORCID,Simonini Americo A.,Yuan Chun,Hatsukami Thomas S.^ORCID,Zhao Xue-Qiao

Funder

Sanofi US

Regeneron Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference48 articles.

1. Cholesterol lowering in intermediate-risk persons without cardiovascular disease;Yusuf;N. Engl. J. Med.,2016

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol;Grundy;Circulation,2019

3. Ezetimibe added to statin therapy after acute coronary syndromes;Cannon;N. Engl. J. Med.,2015

4. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N. Engl. J. Med.,2017

5. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N. Engl. J. Med.,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature;Drugs;2024-01-25

2. What are the benefits and drawbacks of statins in carotid artery disease? A perspective review;Expert Review of Cardiovascular Therapy;2023-11-02

3. Inflammation—The new treatment target for ischaemic stroke prevention;Frontiers in Stroke;2023-10-23

4. Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update;Metabolites;2023-08-04

5. Current and future options in cholesterol lowering treatments;European Journal of Internal Medicine;2023-06